Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
NOVATO, Calif., Oct. 03, 2025 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. ( NASDAQ: RARE ) , a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of non-qualified stock options to ...
Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President
NOVATO, Calif., Sept. 30, 2025 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. ( NASDAQ: RARE ) today announced the appointment of Eric Olson as chief business officer ( CBO ) and executive vice president effective September 22, 2025, following the planned retirement of Thomas Kassberg.
Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President - Ultragenyx Pharmaceutical ( NASDAQ:RARE )
NOVATO, Calif., Sept. 30, 2025 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. ( NASDAQ:RARE ) today announced the appointment of Eric Olson as chief business officer ( CBO ) and executive vice president effective September 22, 2025, following the planned retirement of Thomas Kassberg.
FDA Approves Label Extension of REGN's Cholesterol Drug Evkeeza
Regeneron wins FDA approval to extend Evkeeza use in children as young as one with severe familial hypercholesterolemia.
Evkeeza® ( evinacumab-dgnb ) ANGPTL3 Antibody Approved in the U.S. for Children as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol
FDA approval extends the indication of Evkeeza to treat younger patients with homozygous hypercholesterolemia ...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
NOVATO, Calif., Sept. 19, 2025 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. ( NASDAQ: RARE ) , a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 48,561 restricted stock units of ...
RARE Reports Positive Long-Term Data From Metabolic Disorder Study
Ultragenyx posts 96-week data showing DTX401 sharply cuts cornstarch needs and improves life quality in GSDIa patients.
Ultragenyx Announces Positive Longer-term Data from Phase 3 Study of DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia ( GSDIa )
At Week 96 participants experienced even greater reductions in daily cornstarch intake while maintaining low levels of hypoglycemia, improved levels of euglycemia and improved fasting tolerance ...
Rare Disease Therapy Approvals By FDA Speed Up Via New Process - Neurogene ( NASDAQ:NGNE )
FDA's RDEP may allow approval with one study plus strong supporting evidence. Analysts remain cautious on how RDEP will impact rare therapy timelines. Get Discounted Real-Time Trade Alerts For a Volatile Market ( Labor Day Special ) The U.S.
Ultragenyx to Participate at Investor Conferences in September
NOVATO, Calif., Aug. 29, 2025 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. ( NASDAQ: RARE ) , a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced participation in three upcoming ...
Ultragenyx to Participate at Investor Conferences in September - Ultragenyx Pharmaceutical ( NASDAQ:RARE )
NOVATO, Calif., Aug. 29, 2025 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. RARE, a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced participation in three upcoming investor ...
The Smartest Growth ETF to Buy With $100 Right Now
This ETF minimizes risk and offers strong diversification.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE - Ultragenyx Pharmaceutical ( NASDAQ:RARE )
NEW YORK, Aug. 25, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. ( "Ultragenyx" or the "Company" ) RARE. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
NOVATO, Calif., Aug. 21, 2025 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. ( NASDAQ: RARE ) , a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 113,572 restricted stock units of ...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO - Mereo BioPharma Group ( NASDAQ:MREO )
NEW YORK, Aug. 21, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc ( "Mereo" or the "Company" ) MREO. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE - Ultragenyx Pharmaceutical ( NASDAQ:RARE )
NEW YORK, Aug. 21, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. ( "Ultragenyx" or the "Company" ) RARE. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE - Ultragenyx Pharmaceutical ( NASDAQ:RARE )
NEW YORK, Aug. 17, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. ( "Ultragenyx" or the "Company" ) RARE. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO - Mereo BioPharma Group ( NASDAQ:MREO )
NEW YORK, Aug. 13, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc ( "Mereo" or the "Company" ) MREO. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights
Data from Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta expected around ...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO - Mereo BioPharma Group ( NASDAQ:MREO )
NEW YORK, Aug. 09, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc ( "Mereo" or the "Company" ) MREO. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Ultragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y
RARE posts a narrower Q2 loss and 13% revenue growth as demand rises across all four marketed rare disease drugs.
Ultragenyx ( RARE ) Q2 Revenue Up 13%
Ultragenyx Pharmaceutical ( NASDAQ:RARE ) , a rare disease drug developer, reported its second quarter 2025 earnings on August 5, 2025. Both revenue and earnings per share exceeded Wall Street expectations for the period.
Ultragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate Update
NOVATO, Calif., July 30, 2025 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. ( NASDAQ: RARE ) , a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference ...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO - Mereo BioPharma Group ( NASDAQ:MREO )
NEW YORK, July 28, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc ( "Mereo" or the "Company" ) MREO. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
NOVATO, Calif., July 18, 2025 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. ( NASDAQ: RARE ) , a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 45,292 restricted stock units of the ...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE - Ultragenyx Pharmaceutical ( NASDAQ:RARE )
NEW YORK, July 18, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. ( "Ultragenyx" or the "Company" ) RARE. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
FDA Delays Approval For Ultragenyx's Gene Therapy, But Not A Dealbreaker, Says Analyst - Ultragenyx Pharmaceutical ( NASDAQ:RARE )
FDA issued a Complete Response Letter for Ultragenyx's UX111 gene therapy, citing manufacturing facility issues. Morgan Stanley cuts Ultragenyx's price target to $55 from $65; Wedbush lowers it to $34. PPI and Industrial Production drop Wednesday morning - see how Matt Maley is trading the ...
Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Apple ( NASDAQ:AAPL ) , Above Food Ingredients ( NASDAQ:ABVE )
U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Monday. Shares of Ultragenyx Pharmaceutical Inc. RARE fell sharply in pre-market trading. Ultragenyx received a Complete Response Letter from the FDA for UX111 AAV gene therapy to treat Sanfilippo ...
Ultragenyx Receives Complete Response Letter from FDA for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A ( MPS IIIA )
Complete Response Letter ( CRL ) cited specific chemistry, manufacturing and controls ( CMC ) related observations that are resolvable ...
Ultragenyx Pharmaceutical's Options: A Look at What the Big Money is Thinking - Ultragenyx Pharmaceutical ( NASDAQ:RARE )
Financial giants have made a conspicuous bearish move on Ultragenyx Pharmaceutical. Our analysis of options history for Ultragenyx Pharmaceutical RARE revealed 10 unusual trades. Delving into the details, we found 30% of traders were bullish, while 60% showed bearish tendencies.
Crude Oil Down Over 2%; Delta Air Lines Posts Upbeat Earnings - BIT Mining ( NYSE:BTCM ) , Above Food Ingredients ( NASDAQ:ABVE )
U.S. stocks traded mostly higher midway through trading, with the Dow Jones index gaining more than 200 points on Thursday. The Dow traded up 0.52% to 44,690.50 while the NASDAQ declined 0.03% to 20,605.11. The S&P 500 also rose, gaining, 0.23% to 6,278.25. Health care shares jumped by 1.2% on ...
US Stocks Mixed; Initial Jobless Claims Fall - BIT Mining ( NYSE:BTCM ) , Above Food Ingredients ( NASDAQ:ABVE )
U.S. stocks traded mixed this morning, with the Dow Jones index gaining around 100 points on Thursday. Following the market opening Thursday, the Dow traded up 0.24% to 44,564.14 while the NASDAQ declined 0.44% to 20,520.54. The S&P 500 also fell, dropping, 0.09% to 6,257.81.
RARE, MREO Fall as Osteogenesis Study Likely to Continue Till Year End
Ultragenyx Pharmaceutical and Mereo BioPharma shares tumble as investors await key phase III UX143 osteogenesis data now set for release at year-end.
Why Are Biotech Stocks Ultragenyx And Mereo Facing A Sell-Off? - Ultragenyx Pharmaceutical ( NASDAQ:RARE ) , Mereo BioPharma Group ( NASDAQ:MREO )
UX143 Phase 3 trial will continue to final analysis as interim data did not meet early stopping criteria ( p<0.01 ) . Final analysis for Orbit and Cosmic trials expected by year-end, with thresholds of p<0.04 and p<0.05 respectively. Up Next: Get 5 Dark Horse Stocks Wall Street Is Quietly ...
Methode Electronics, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - BitMine Immersion Techs ( AMEX:BMNR ) , Altimmune ( NASDAQ:ALT )
U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Thursday. Shares of Methode Electronics, Inc. MEI fell sharply in today's pre-market trading after the company reported a fourth-quarter adjusted EPS miss.
RARE's GTX-102 Gets FDA's Breakthrough Status for Angelman Syndrome
Ultragenyx Pharmaceuticals' GTX-102 earns FDA Breakthrough status after early data shows sustained progress in Angelman syndrome patients.
Ultragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome - Ultragenyx Pharmaceutical ( NASDAQ:RARE )
Phase 3 Aspire study enrollment on track to complete in 2025 Aurora study to evaluate GTX-102 in other Angelman syndrome genotypes and ages expected to initiate later this year NOVATO, Calif., June 27, 2025 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc.
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Ultragenyx Pharmaceutical ( NASDAQ:RARE )
NOVATO, Calif., June 20, 2025 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. RARE, a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 48,731 restricted stock units of the company's ...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
NOVATO, Calif., June 20, 2025 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. ( NASDAQ: RARE ) , a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 48,731 restricted stock units of the ...
Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference
NOVATO, Calif., June 03, 2025 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. ( NASDAQ: RARE ) , a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil Kakkis, M.D., Ph.D., ...
Analyst Bullish On Ultragenyx, Poised For Growth With Six Drug Approvals Expected By 2028 - Ultragenyx Pharmaceutical ( NASDAQ:RARE )
Ultragenyx's Q1 2025 revenue rose 28% to $139.29 million; full-year guidance was set at $640 million-$670 million. Setrusumab is projected to generate $2.4 billion in peak sales by 2037, with $1.4 billion to Ultragenyx.
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
NOVATO, Calif., May 20, 2025 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. ( NASDAQ: RARE ) , a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 44,805 restricted stock units of the ...
Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report - Ultragenyx Pharmaceutical ( NASDAQ:RARE )
NOVATO, Calif., May 14, 2025 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. RARE released its 2024 Impact Report today, which covers the company's approach to corporate responsibility.
Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report
NOVATO, Calif., May 14, 2025 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. ( NASDAQ: RARE ) released its 2024 Impact Report today, which covers the company's approach to corporate responsibility. The report highlights efforts to transform the lives of individuals and families affected by ...
Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights
Progress continues in Phase 3 Orbit study of setrusumab in osteogenesis ...
Ultragenyx's Q1 Loss Wider Than Expected, Revenues Increase Y/Y
RARE reports weaker-than-expected first-quarter results, as earnings and revenues miss estimates despite a year-over-year increase in product sales.
5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates
Let us look at some drug/biotech stocks, NVO, PCRX, RARE, ACAD and DNLI, which are poised to beat on first-quarter 2025 earnings.
Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate Update - Ultragenyx Pharmaceutical ( NASDAQ:RARE )
NOVATO, Calif., April 30, 2025 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. RARE, a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call at 5:00 ...
Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate Update
NOVATO, Calif., April 30, 2025 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. ( NASDAQ: RARE ) , a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference ...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
NOVATO, Calif., April 22, 2025 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. ( NASDAQ: RARE ) , a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 36,831 restricted stock units of the ...
